Sign in
CompletedPhase 3

Alternative Antibiotics for Syphilis

Key facts

Who runs it
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Where
Spain and United Kingdom11 sites in 2 countriesChoose a country to see its sites
Status
Completed
Phase
Phase 3
People taking part
165 people enrolled
Started
14 Oct 2021
Ended
15 Apr 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Linezolid 600 mg (post-interim)
  • Benzathine Penicilllin G (post-interim)
Record updated
29 July 2026

Who can take part

Age
18 years to 99 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Age 18 years or older at baseline visit
  • Primary, secondary or early latent syphilis diagnosis based on SEIMC/IUSTI Guidelines*; Primary syphilis is defined as typical ulcer (chancre) and one of the following: detection of T.p. by Polymerase chain reaction (PCR), positive darkfield examination (DFE) or positive serological test (RPR≥1:4) for syphilis; Secondary syphilis is defined based on typical clinical symptoms with positive treponemal and non-treponemal tests (RPR≥1:4); Early latent syphilis is defined as positive serological treponemal and non-treponemal tests (RPR≥1:4) with no clinical evidence of infection, with a previous negative syphilis serology,or a four-fold increase in RPR titer of a non-treponemal test within the past 12 months.Serological tests for syphilis performed within 10 days prior to study inclusion visit willbe acceptable for enrollment
  • Signature of written informed consent
  • Ability to comply with the requirements of the study protocol
  • If women of childbearing potential, use of a highly effective method of contraception (abstinence,hormonal contraception, intra-uterine device [IUD], or anatomical sterility in self or partner)committed during 1 week after last IMP administration
  • If men, use of condom during heterosexual intercourse and use of a highly effective method ofcontraception (abstinence, hormonal contraception, intra-uterine device [IUD], or anatomical sterilityin self or partner) in female partner committed during 1 week after last IMP administration; For inclusion purposes, positive point of care tests (POCT) will be accepted in selected patients without previous syphilis history and negative serological tests for syphilis during the last 12 months (Syphilis rapid diagnostic test [RDT] or Chembio DPP syphilis screen \& confirm assay [DPP]), or with a previous history of syphilis and negative non-treponemal tests during the last 12 months (DPP). Further confirmation by the methods described in a), b) or c) will be necessary. Participants whose diagnosis is not confirmed will be excluded from the efficacy analyses

Who cannot take part

  • Current treatment with any drugs likely to interact with the study medication (see Appendix 6)
  • Have taken any antibiotics with potential activity against syphilis (e.g. beta lactams, cephalosporines, macrolides, tetracyclines) within 1 week prior to randomization
  • Symptomatic concomitant STI (i.e., gonococcus, chlamydia, lymphogranuloma venereum, Mycoplasma genitalium) or other infection disease requiring antibiotic treatment potentially active against syphilis
  • Having received treatment for the early syphilis recently diagnosed (In the previous 6 months)
  • Known allergy to any of the IMPs and/or excipients, particularly known hypersensitivity to penicillin, cephalosporins or other beta-lactam agents and/or allergy to soya or peanut
  • Uncontrolled hypertension, pheochromocytoma, thyrotoxicosis, carcinoid syndrome, bipolar disorder, incapacitating psycho-affective disturbance, acute confusional state
  • Renal function impairment requiring hemodialysis
  • Lactose or galactose intolerance or glucose-galactose malabsorbtion
  • Diagnosis criteria of symptomatic neurosyphilis
  • Pregnant or breastfeeding women

This trial has no sites in United States.

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The Trep-AB clinical trial will test the efficacy of an investigational neuropenetrative drug, Linezolid (LZD), compared to standard treatment, Benzathine penicillin G (BPG), for early syphilis in humans. The overarching idea of the work proposed herein is to investigate the use of LZD to treat syphilis, conducting a randomized controlled clinical trial to evaluate this new indication of a known antibacterial agent.

The 2 groups in the trial

  • Post-interim - Linezolid 600 mg every 12 hours for 10 daysTreatment being tested

    After randomized to the experimental arm, the patient will take 1 tablet of Linezolid every 12hours during 10 days.

    Treatment: Linezolid 600 mg (post-interim)

  • Post-interim - Benzathine penicillin G 2.4 MUI single doseExisting treatment, for comparison

    After randomized to the control arm, the patient will receive a single dose of 2.4MUI intramuscular BPG.

    Treatment: Benzathine Penicilllin G (post-interim)

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Oral and Neuro-Penetrative Alternative Antibiotics for Patients With Syphilis
Publications
Record updated
29 July 2026